Target
KDM6A
3 abstracts
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer.Org: Aarhus University Hospital, C2i Genomics Inc., C2i Genomics Ltd.,
Abstract
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, MD Anderson Hematology/Oncology Fellowship, The Medical College of Wisconsin,